Icecure Medical is trading at $3.24 (+5.23%) after recent momentum followed Adventist Health Glendale becoming the first approved enrollment site for IceCure Medical’s post-marketing ChoICE study.
- No new company-specific announcement for August 10, 2026 was identified that directly explains the move.
- Investors may be positioning ahead of August 12, 2026, when the company is scheduled to report first-half results.
- With major indexes mixed, the immediate catalyst remains unconfirmed.